Skip to main content
Article thumbnail
Location of Repository

Redemptive benefit of atorvastatin in the risk factors of coronary artery disease

By Kalaiyarasan Vijaya Kumar Int J Cur Biomed Phar Res. Palanisamy Sampath Kumar Subramaniyam Kalavathy Govindha Raj Archunan Shanmugam Achiraman Arumugam Vijaya Anand Jayaraman Gowri


Cardiovascular disease, in particular coronary artery disease (CAD), is the principal cause of mortality in developed countries. The classical acute phase protein, C-reactive protein (CRP) is an exquisitely sensitive systemic marker of disease with broad clinical utility for monitoring and differential diagnosis. In recent years, acute phase reactants have been shown to predict future cardiovascular events in individuals with and without established CAD. Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, substantially reduce cardiovascular morbidity and mortality, and recently their anti-inflammatory properties have been investigated. The present study was therefore designed to determine the effects of atorvastatin on CRP in patients with CAD. Ninety two patients with or without or at the risk of CAD were recruited for the study, of which 35 belongs to control (untreated) and 57 were test group, in which, 30 of them received daily with 20 mg/day of atorvastatin and the remaining 27 were untreated. The patients were followed for over a period of 6 weeks. For entire study population, CRP along with lipid profile, SGOT, SGPT, urea and creatinine were measured 1st day and at the end of 6th week of the treatment. For patients with or at risk of CAD, the reduced rate of progression of atherosclerosis associated with intensive atorvastatin treatment, as compared with control is significantly related to greater reduction in the levels of both atherogenic lipoproteins and CRP. This may be important with respect to the early benefits of atorvastatin therapy

Publisher: CurrentSciDirect Publications
Year: 2011
OAI identifier:

Suggested articles


  1. (2001). a hydroxy methyl coenzyme A inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. doi
  2. (1998). Antiatherothrombotic properties of statins: implications for cardiovascular event reduction [Review].
  3. (2002). ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastin on carotid intima medical thickness. Circulation.
  4. (1999). Atherosclerosis involves more than just lipids: plaque dynamics. Eur Heart
  5. (1999). Bazzino OO. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation.
  6. (2004). Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc.
  7. (2002). Effects of simvastatin and atorvastin on inflammation markers in plasma. doi
  8. (2000). High-sensitivity C-reactive protein and atherosclerosis from theory to therapy. Clin Biochem.
  9. (1999). Long term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation.
  10. (2005). Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis
  11. (1998). Statins as cellular antithrombotics. Haemostasis.
  12. (2001). The PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort
  13. (1998). Unstable atheroslerotic plaque: pathophysiology and therapeutic guidelinpes. Acta Cardiol.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.